Israeli pharmaceutical giant Teva has announced the launch of the first available generic version of a nasal spray used to treat opioid overdose.
Naloxone hydrochloride nasal spray, currently sold under the brand name Narcan, is used in emergencies to block the effects of opioid drugs.
The US has in recent years faced a crisis over opioid drug addiction, which has caused more than 500,000 overdose deaths in the country over the past 20 years.
Teva has itself been accused, along with other major pharmaceutical companies, of stoking the opioid epidemic by engaging in misleading marketing of opioid drugs and downplaying the risks of addiction. Drugmakers and distributors are facing thousands of legal claims by state and local authorities over the crisis.
In September Teva reached an agreement with the attorney general of Louisiana to pay $15 million to settle the state’s opioid-related claims and to provide an additional donation of medicines that aid in opioid addiction and recovery, valued at $3 million.
Get The Times of Israel's Daily Edition
by email and never miss our top stories
By signing up, you agree to the
terms
Your next read: ToI Editors' Picks
LIMITED TIME OFFER: Join The Times of Israel Community today and you'll receive a physical book of your choice, carefully curated by our editors.
Choose between two must-reads: When We See You Again by Rachel Goldberg-Polin, a searing portrait of a mother’s grief and strength following unthinkable tragedy;
Or Out of the Sky: Heroism and Rebirth in Nazi Europe by Matti Friedman, the gripping and surprising tale of a forgotten moment during World War II.
As a Community member, you’ll also enjoy our DocuNation series of outstanding Israeli documentary films, an ad-free experience of our site and podcasts, commenting privileges, and more.
CHOOSE YOUR BOOK
CHOOSE YOUR BOOK
Already a member? Sign in to stop seeing this
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this